Record Revenue and Earnings
Globus
Medical, Inc. (NYSE:GMED), a leading spinal implant manufacturer,
today announced its financial results for the year and fourth quarter
ended December 31, 2012.
Full Year 2012:
-
Worldwide sales were $386.0 million, up 16.4% over 2011
-
Net income increased 21.5% to $73.8 million compared to $60.8 million
in 2011
-
2012 earnings per fully diluted share increased 19.4% to $0.80
compared to $0.67 in 2011
-
Non-GAAP Adjusted EBITDA was 35.4% of sales, compared to 35.8% in 2011
Fourth Quarter:
-
Worldwide sales were $100.5 million, a 14.3% increase from the fourth
quarter of 2011
-
Fourth quarter net income increased by 53.0% to $20.8 million compared
to $13.6 million in 2011
-
Earnings per fully diluted share increased 46.7% in the fourth quarter
of 2012 to $0.22 compared to $0.15 for the same quarter of 2011
-
Non-GAAP Adjusted EBITDA was 34.6% of sales, compared to 34.4% in the
fourth quarter of 2011
David Paul, Chairman and CEO, commented, “2012 was a tremendous year for
Globus with industry leading revenue growth, continued strong
profitability, the completion of a successful IPO, and the launch of 14
new products, including our first PMA approval with the SECURE®-C
device. Our product development engine continues to perform at a high
level creating the solutions of tomorrow for patients with spinal
disorders."
Dave Demski, President and COO, added, "We performed extremely well in
the fourth quarter with record sales of $100.5 million and an increase
in diluted EPS of 46.7% over fourth quarter 2011. We maintained the
strong pace of our U.S. sales force recruitment. Outside the United
States, we added new distribution territories, providing us with a sales
presence in 24 countries. Late in the quarter, we purchased a 112,000
square foot building adjacent to our existing facility. With nearly
250,000 square feet of real estate, we have adequate space to support
our future growth. In the fourth quarter we generated $17.2 million of
cash flow and achieved 34.6% adjusted EBITDA despite our continuing
investment in Algea
Therapies. Excluding investments made in Algea
Therapies, our adjusted EBITDA for the fourth quarter was 38.0%."
Cash and cash equivalents ended the year at $212.4 million, increasing
by $69.7 million during year, which was inclusive of proceeds from the
company's IPO, acquisitions, facility purchase, and product launch
capital expenditures. The company remains debt free.
Conference Call Information
Globus Medical will hold a teleconference to discuss its performance
with the investment community at 5:30 p.m. Eastern Time today. Globus
invites all interested parties to join the call by dialing:
|
|
|
|
|
|
|
1-855-533-7141
|
|
|
|
|
|
|
United States Participants
|
|
|
|
|
|
|
|
1-720-545-0060
|
|
|
|
|
|
|
International Participants
|
|
|
|
|
|
|
|
There is no pass code for the teleconference.
|
For interested parties who do not wish to ask questions, the
teleconference will be webcast live and may be accessed through a link
on the Globus Medical website at investors.globusmedical.com.
If you are unable to participate during the live teleconference, the
call will be archived until Wednesday, March 13, 2013. The audio archive
can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406
from outside the U.S. The pass code for the audio replay is 1075-3353.
About Globus Medical, Inc.
Globus
Medical, Inc. is a leading spinal implant manufacturer based in
Audubon, Pennsylvania. The company was founded in 2003 by an experienced
team of spine professionals with a shared vision to create products that
enable spine surgeons to promote healing in patients with spinal
disorders.
Non-GAAP Financial Measures
Adjusted EBITDA represents net income before interest (income)/expense,
net and other non-operating expenses, provision for income taxes,
depreciation and amortization, stock-based compensation, changes in the
fair value of contingent consideration in connection with business
acquisitions and provision for litigation settlements. This financial
measure is not calculated in conformity with accounting principles
generally accepted in the United States of America (GAAP). We present
Adjusted EBITDA because we believe it is a useful indicator of our
operating performance. Our management uses Adjusted EBITDA principally
as a measure of our operating performance and believes that Adjusted
EBITDA is useful to investors because it is frequently used by
securities analysts, investors and other interested parties in their
evaluation of the operating performance of companies in industries
similar to ours. We also believe Adjusted EBITDA is useful to our
management and investors as a measure of comparative operating
performance from period to period and among companies as it is
reflective of changes in pricing decisions, cost controls and other
factors that affect operating performance, and it removes the effect of
our capital structure (primarily interest expense), asset base
(primarily depreciation and amortization) and items outside the control
of our management (primarily income taxes and interest income and
expense). Our management also uses Adjusted EBITDA for planning
purposes, including the preparation of our annual operating budget and
financial projections.
Adjusted EBITDA should not be considered in isolation or as a substitute
for a measure of our liquidity or operating performance prepared in
accordance with GAAP, and is not indicative of net income (loss) from
operations as determined under GAAP. Adjusted EBITDA and other non-GAAP
financial measures have limitations that should be considered before
using these measures to evaluate our liquidity or financial performance.
Adjusted EBITDA does not include certain expenses that may be necessary
to review our operating results and liquidity requirements. Our
definition and calculation of Adjusted EBITDA may differ from that of
other companies.
Safe Harbor Statements
All statements included in this press release other than statements of
historical fact are forward-looking statements and may be identified by
their use of words such as “believe,” “may,” “might,” “could,” “will,”
“aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan”
and other similar terms. These forward-looking statements are based on
our current assumptions, expectations and estimates of future events and
trends. Forward-looking statements are only predictions and are subject
to many risks, uncertainties and other factors that may affect our
businesses and operations and could cause actual results to differ
materially from those predicted. These risks and uncertainties include,
but are not limited to, factors affecting our quarterly results, our
ability to manage our growth, our ability to sustain our profitability,
demand for our products, our ability to compete successfully (including
without limitation our ability to convince surgeons to use our products
and our ability to attract and retain sales and other personnel), our
ability to rapidly develop and introduce new products, our ability to
develop and execute on successful business strategies, our ability to
comply with changing laws and regulations that are applicable to our
businesses, our ability to safeguard our intellectual property, our
success in defending legal proceedings brought against us, trends in the
medical device industry, general economic conditions, and other risks.
For a discussion of these and other risks, uncertainties and other
factors that could affect our results, you should refer to the
disclosure contained in our prospectus filed with the Securities and
Exchange Commission on August 3, 2012, as amended, including the
sections labeled “Risk Factors,” “Cautionary Note Concerning
Forward-Looking Statements,” and “Management's Discussion and Analysis
of Financial Condition and Results of Operations,” and in our periodic
reports on file with the Securities and Exchange Commission. These
documents are available at www.sec.gov.
Moreover, we operate in an evolving environment. New risk factors and
uncertainties emerge from time to time and it is not possible for us to
predict all risk factors and uncertainties, nor can we assess the impact
of all factors on its business or the extent to which any factor, or
combination of factors, may cause actual results to differ materially
from those contained in any forward-looking statements. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on any forward-looking statements. Forward-looking statements
contained in this press release speak only as of the date of this press
release. We undertake no obligation to update any forward-looking
statements as a result of new information, events or circumstances or
other factors arising or coming to our attention after the date hereof.
|
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF INCOME
|
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Year Ended
|
(In thousands, except per share amounts)
|
|
December 31, 2012
|
|
December 31, 2011
|
|
December 31, 2012
|
|
December 31, 2011
|
Sales
|
|
$
|
100,536
|
|
|
$
|
87,993
|
|
|
$
|
385,994
|
|
|
$
|
331,478
|
|
Cost of goods sold
|
|
|
19,557
|
|
|
|
19,487
|
|
|
|
75,199
|
|
|
|
68,796
|
|
Gross profit
|
|
|
80,979
|
|
|
|
68,506
|
|
|
|
310,795
|
|
|
|
262,682
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
7,228
|
|
|
|
5,773
|
|
|
|
27,926
|
|
|
|
23,464
|
|
Selling, general and administrative
|
|
|
44,626
|
|
|
|
37,857
|
|
|
|
168,862
|
|
|
|
140,386
|
|
Provision for litigation settlements
|
|
|
15
|
|
|
|
1,164
|
|
|
|
(786
|
)
|
|
|
1,470
|
|
Total operating expenses
|
|
|
51,869
|
|
|
|
44,794
|
|
|
|
196,002
|
|
|
|
165,320
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
29,110
|
|
|
|
23,712
|
|
|
|
114,793
|
|
|
|
97,362
|
|
Other expense, net
|
|
|
(16
|
)
|
|
|
(220
|
)
|
|
|
(140
|
)
|
|
|
(413
|
)
|
Income before income taxes
|
|
|
29,094
|
|
|
|
23,492
|
|
|
|
114,653
|
|
|
|
96,949
|
|
Income tax provision
|
|
|
8,327
|
|
|
|
9,922
|
|
|
|
40,822
|
|
|
|
36,165
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
20,767
|
|
|
$
|
13,570
|
|
|
$
|
73,831
|
|
|
$
|
60,784
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
0.23
|
|
|
$
|
0.15
|
|
|
$
|
0.82
|
|
|
$
|
0.69
|
|
Diluted
|
|
$
|
0.22
|
|
|
$
|
0.15
|
|
|
$
|
0.80
|
|
|
$
|
0.67
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
91,177
|
|
|
|
88,093
|
|
|
|
89,608
|
|
|
|
88,112
|
|
Diluted
|
|
|
93,456
|
|
|
|
90,337
|
|
|
|
92,208
|
|
|
|
90,420
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
|
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
(In thousands, except par value)
|
|
|
December 31, 2012
|
|
|
December 31, 2011
|
|
|
|
(unaudited)
|
|
|
|
ASSETS
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
212,400
|
|
|
$
|
142,668
|
|
Accounts receivable, net of allowances of $961 and $602, respectively
|
|
|
53,496
|
|
|
|
46,727
|
|
Inventories
|
|
|
62,310
|
|
|
|
47,369
|
|
Prepaid expenses and other current assets
|
|
|
3,020
|
|
|
|
2,515
|
|
Income taxes receivable
|
|
|
5,105
|
|
|
|
3,336
|
|
Deferred income taxes
|
|
|
23,779
|
|
|
|
16,160
|
|
Total current assets
|
|
|
360,110
|
|
|
|
258,775
|
|
Property and equipment, net
|
|
|
61,089
|
|
|
|
52,394
|
|
Intangible assets, net
|
|
|
9,585
|
|
|
|
7,433
|
|
Goodwill
|
|
|
15,372
|
|
|
|
9,808
|
|
Other assets
|
|
|
977
|
|
|
|
980
|
|
Total assets
|
|
$
|
447,133
|
|
|
$
|
329,390
|
|
|
|
|
|
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
9,991
|
|
|
$
|
5,323
|
|
Accounts payable to related party
|
|
|
2,556
|
|
|
|
1,178
|
|
Accrued expenses
|
|
|
25,003
|
|
|
|
21,268
|
|
Income taxes payable
|
|
|
523
|
|
|
|
302
|
|
Business acquisition liabilities, current
|
|
|
1,435
|
|
|
|
1,200
|
|
Total current liabilities
|
|
|
39,508
|
|
|
|
29,271
|
|
Business acquisition liabilities, net of current portion
|
|
|
9,909
|
|
|
|
9,089
|
|
Deferred income taxes
|
|
|
7,714
|
|
|
|
5,755
|
|
Other liabilities
|
|
|
3,500
|
|
|
|
2,799
|
|
Total liabilities
|
|
|
60,631
|
|
|
|
46,914
|
|
Commitments and contingencies
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
Convertible preferred stock; $0.001 par value. Authorized 50,961
shares; issued and outstanding 0 and 50,961 shares at December 31,
2012 and 2011, respectively
|
|
|
—
|
|
|
|
51
|
|
Common stock; $0.001 par value. Authorized 785,000 and 679,178
shares; issued and outstanding 91,270 and 72,529 shares at December
31, 2012 and 2011, respectively
|
|
|
91
|
|
|
|
73
|
|
Additional paid-in capital
|
|
|
136,501
|
|
|
|
106,708
|
|
Accumulated other comprehensive loss
|
|
|
(767
|
)
|
|
|
(1,202
|
)
|
Retained earnings
|
|
|
250,677
|
|
|
|
176,846
|
|
Total equity
|
|
|
386,502
|
|
|
|
282,476
|
|
Total liabilities and equity
|
|
$
|
447,133
|
|
|
$
|
329,390
|
|
|
|
|
|
|
|
|
|
|
GLOBUS MEDICAL, INC. AND SUBSIDIARIES
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
Year Ended
|
(In thousands)
|
|
|
December 31, 2012
|
|
|
December 31, 2011
|
|
|
|
(unaudited)
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
Net income
|
|
$
|
73,831
|
|
|
$
|
60,784
|
|
Adjustments to reconcile net income to net cash provided by
operating activities
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
18,108
|
|
|
|
16,949
|
|
Provision for excess and obsolete inventories
|
|
|
6,119
|
|
|
|
10,487
|
|
Stock-based compensation
|
|
|
4,635
|
|
|
|
3,286
|
|
Allowance for doubtful accounts
|
|
|
363
|
|
|
|
105
|
|
Change in fair value of interest rate swap
|
|
|
—
|
|
|
|
113
|
|
Change in fair value of contingent consideration
|
|
|
119
|
|
|
|
(79
|
)
|
Change in deferred income taxes
|
|
|
(6,079
|
)
|
|
|
2,057
|
|
(Increase) decrease in:
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(6,886
|
)
|
|
|
(4,672
|
)
|
Inventories
|
|
|
(20,541
|
)
|
|
|
(15,280
|
)
|
Prepaid expenses and other assets
|
|
|
(117
|
)
|
|
|
460
|
|
Increase (decrease) in:
|
|
|
|
|
|
|
Accounts payable
|
|
|
3,048
|
|
|
|
(1,355
|
)
|
Accounts payable to related party
|
|
|
1,378
|
|
|
|
(696
|
)
|
Accrued expenses and other liabilities
|
|
|
4,089
|
|
|
|
1,541
|
|
Income taxes payable/receivable
|
|
|
(1,548
|
)
|
|
|
2,710
|
|
Net cash provided by operating activities
|
|
|
76,519
|
|
|
|
76,410
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
Purchases of property and equipment
|
|
|
(24,684
|
)
|
|
|
(22,487
|
)
|
Acquisition of businesses
|
|
|
(6,031
|
)
|
|
|
(7,500
|
)
|
Net cash used in investing activities
|
|
|
(30,715
|
)
|
|
|
(29,987
|
)
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
Repayments of long-term debt
|
|
|
—
|
|
|
|
(5,253
|
)
|
Payment of business acquisition liabilities
|
|
|
(1,100
|
)
|
|
|
(400
|
)
|
Net proceeds from initial public offering
|
|
|
20,960
|
|
|
|
—
|
|
Net proceeds from issuance of common stock
|
|
|
1,504
|
|
|
|
886
|
|
Purchase of common stock
|
|
|
—
|
|
|
|
(10,021
|
)
|
Excess tax benefit related to nonqualified stock options
|
|
|
2,661
|
|
|
|
54
|
|
Net cash provided by/(used in) financing activities
|
|
|
24,025
|
|
|
|
(14,734
|
)
|
|
|
|
|
|
|
|
Effect of foreign exchange rate on cash
|
|
|
(97
|
)
|
|
|
(722
|
)
|
|
|
|
|
|
|
|
Net increase in cash and cash equivalents
|
|
|
69,732
|
|
|
|
30,967
|
|
Cash and cash equivalents, beginning of period
|
|
|
142,668
|
|
|
|
111,701
|
|
Cash and cash equivalents, end of period
|
|
$
|
212,400
|
|
|
$
|
142,668
|
|
|
|
|
|
|
|
|
Supplemental disclosures of cash flow information:
|
|
|
|
|
|
|
Interest paid
|
|
|
63
|
|
|
|
167
|
|
Income taxes paid
|
|
$
|
44,875
|
|
|
$
|
35,721
|
|
|
|
|
|
|
|
|
|
|
The following is a reconciliation of Adjusted EBITDA (unaudited) to net
income for the periods presented:
|
|
|
|
|
|
|
Three Months Ended
|
|
Year Ended
|
|
|
December 31,
|
|
December 31,
|
|
December 31,
|
|
December 31,
|
(In thousands, except percentages)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
Net Income
|
|
$
|
20,767
|
|
|
$
|
13,570
|
|
|
$
|
73,831
|
|
|
$
|
60,784
|
|
Interest (income)/expense, net
|
|
(5
|
)
|
|
(19
|
)
|
|
(80
|
)
|
|
33
|
|
Provision for income taxes
|
|
8,327
|
|
|
9,922
|
|
|
40,822
|
|
|
36,165
|
|
Depreciation and amortization
|
|
4,608
|
|
|
4,747
|
|
|
18,108
|
|
|
16,949
|
|
EBITDA
|
|
33,697
|
|
|
28,220
|
|
|
132,681
|
|
|
113,931
|
|
Stock-based compensation
|
|
953
|
|
|
1,135
|
|
|
4,635
|
|
|
3,286
|
|
Provision for legal settlements
|
|
15
|
|
|
1,164
|
|
|
(786
|
)
|
|
1,470
|
|
Change in fair value of contingent consideration
|
|
96
|
|
|
(261
|
)
|
|
119
|
|
|
(79
|
)
|
Adjusted EBITDA
|
|
$
|
34,761
|
|
|
$
|
30,258
|
|
|
$
|
136,649
|
|
|
$
|
118,608
|
|
Adjusted EBITDA as a percentage of sales
|
|
34.6
|
%
|
|
34.4
|
%
|
|
35.4
|
%
|
|
35.8
|
%
|
|
|
|
|
|
|
|
|
|